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Abstract  
World pharmaceutical industry has been changing profoundly as it has been steadily concentrating and 
consolidating in the last decade. According to our survey, we may underline the intensive marketing 
management represents an extremely important operational and even strategic function for proper business 
performance and long-term strategic orientation for the world pharmaceutical companies. We may even 
conclude that intensive consolidation of world pharmaceutical industry is a market driven and conditioned by 
strategic marketing management issues. We may estimate that marketing management is to play even more 
important and especially the highest top priority strategic role in the future globalization and consolidation 
processes of world pharmaceutical industry.         
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1. Introduction  
We may define the major characteristics of 
the world pharmaceutical industry as 
follows:  
• increased globalization, 
• changing structure of competition and 
increased competitiveness, 
• lack of brand new products, despite 
increased investments into R&D 
(Research & Development) activities, 
• increased importance of regulatory 
issues (registrations, intellectual 
property rights, litigations), 
• fast consolidation and concentration of 
the world pharmaceutical industry, 
• increased importance of marketing 
management, 
• development of new therapeutic fields 
and technologies (biotechnology, 
pharmacogenomics), 
• ageing of the world population and 
opening up of new, not yet covered 
therapeutic fields,    
• quick development of world generic 
markets. 
 
World pharmaceutical market has 
undergone fast, unprecedented, 
tremendous and complex changes in the 
last several years. We may say that 
pharmaceutical industry has been adapting 
itself more to the market trends and market 
demands. Further strategic development of 
the world pharmaceutical industry shows  
 
relatively clearly its significant 
consolidation and concentration and strong 
market orientation. Pharmaceutical 
industry today probably unite the biggest 
of all mankind potentials. Development of 
brand new drug is today estimated to need 
investment over 1.2 billion $ and takes 
over 12 years to bring it as a finished, 
legally registered and approved product to 
a market place (Pharma Strategy Group 
2007, p.43). This is at the same time very 
complex, comprehensive and highly risky 
job with no final guarantee that a new 
product might succeed onto the market and 
bring revenues back. If a pharmaceutical 
company wants to achieve with a brand 
new product the market success, it needs to 
invest heavily into marketing and sales 
activities.Thus is by no surprise as we may 
conclude that basic research and 
development activities (R&D) together 
with marketing and sales  activities are two 
the most important operative and even 
more strategic activities of the world 
pharmaceutical industry. Here the biggest 
investments of the pharmaceutical industry 
are poured by all means. Having analysed 
these figures, we have found that the 
biggest, innventive  pharmaceutical 
companies invest on average around 16% 
of their sales into R&D and even more, 
around 25% or even more, into marketing 
and sales activities (Kesic 2006, p.22). 
However, these ratios, especially these 
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ones for R&D investments, are even 
higher with specialists, like biotechnology 
and pharmacogenomic pharmaceutical 
companies, and much lower with generic 
pharmaceutical companies (Kesic 2006, p. 
28). As mentioned, world pharmaceutical 
industry is structurally not unique, as 
pharmaceutical companies differ according 
to their basic performance, vision and 
strategic development . We may define 
three different groups of the world 
pharmaceutical companies: 
 
• pharmaceutical companies which 
primarily work on basic research, 
development and marketing and sales 
of brand new, innventive, original 
pharmaceutical products (so called 
originators), 
• pharmaceutical companies which 
primarily work on development and 
sales of generic products (so called 
generic or copycat producers), 
• pharmaceutical companies which 
primarily work on basic research and 
development of biotechnology and 
pharmacogenomic products and 
technologies of new delivery systems 
(so called specialists). 
 
The world pharmaceutical market has been 
growing steadily in the last years. In the 
year 2008, a world pharmaceutical market 
achieved total sales of 715 billion $ and 
growth rate of 4.5 % (World Review 2009, 
p.7). The fastest growing world markets 
and regions are the markets of China, 
India, Central East Europe region (Russia, 
Poland) and certain markets of Latin 
America (Brazil, Mexico). It is estimated 
that the world pharmaceutical market will 
grow by an average 5% CAGR 
(Compounded Annual Growth Rate) till 
the year 2016 (Pharma Strategy Group 
2008, p.34).  
 
 
Table 1: World pharmaceutical market 
from the 2004-2008 
 
Year Value in bn $  Growth in % 
2004          547   11.6 
2005           602   10  
2006          643     7 
2007          684   6.4 
2008          715   4.5 
Source: adapted from World Review 2009  
 
We may argue that products are by no 
means the main drivers for growth of the 
world pharmaceutical industry. 
Pharmaceutical companies strongly 
compete on products' characteristics and 
tend to invest heavily into marketing 
activities in endeavour to gain 
prescribers/patients loyalty and to compete 
as well directly with other  pharmaceutical 
companies. 
 
Table 2: Leading world pharmaceutical 
companies in the 2008* 
 
Posit
ion 
Company Countr
y of 
origin 
Sal
es 
in 
bn 
$  
Wor
ld 
mar
ket 
shar
e in 
% 
 1. Pfizer    USA       
44.
2  
      
6.2 
 2. sanofi-
aventis 
   
France  
      
37.
8  
      
5.3 
 3. GlaxoSmit
hKline 
   Great 
Britain 
      
37.
7 
      
5.2 
 4. Roche    
Switzer
land 
      
33.
2 
      
4.6 
 5. AstraZenec
a 
   Great 
Britain 
      
31.
6 
      
4.4 
 6. Novartis    
Switzer
land 
      
28.
1 
      
3.9 
 7. Johnson&J
ohnson 
   USA       
24.
      
3.4 
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 8. Merck&Co.    USA       
23.
9 
      
3.3 
 9. E.Lilly    USA       
20.
4 
      
2.9 
10. Wyeth    USA       
19.
0 
      
2.7 
* - according to consolidated sales of 
pharmaceuticals and vaccines 
Source:  adapted from the companies 
official published reports 
 
The leading ten world pharmaceutical 
companies currently command over 42 % 
market share of the global pharmaceutical 
market. For comparison reference, this 
figure was only 30 % ten years ago. This is 
a clear sign and proof how intensive 
market consolidation and concentration of 
the world pharmaceutical industry has 
changed world pharmaceutical market in 
the last several years.      
 
The world pharmaceutical industry has 
undergone deep changes in the last decade. 
Most notably, the strong process of 
consolidation and concentration has been 
going on, practically in all three defined 
pharmaceutical sectors; numerous mergers 
and acquisitions have occured, resulting in 
the forming of complete new companies, 
respectively. We may argue that 
competitiveness in the world 
pharmaceutical industry has been 
increasing tremendously. We have 
analysed and scrutinized a whole business 
chain in the pharmaceutical performance 
and found that, for a proper understanding 
and valuation, someone needs to entirely 
monitor the ''Whole 11-P chain circle 
(product, patent, price, place, promotion, 
payers, providers, physicians, pharmacists, 
pharmaceutical industry, patients)'' (Kesic 
2000, p. 31) to get a relevant picture in the 
whole process, coming from a rough idea 
(what is to be a future medicine) till giving 
a final user (patient) a proper ailment relief 
.         
 
Figure 3: 11-P chain circle 
 
productpatentpriceplacepromotio
npayersprovidersphysicianspharm
acistspharmaceutical industrypatients            
Source: Kesic 2000, p. 31 
      
We may forecast that, taking into account 
the mentioned factors, further 
consolidation and concentration of the 
world pharmaceutical industry is 
realistically expected. We may foresee a 
formation of even bigger pharmaceutical 
concerns in all three sectors of the 
pharmaceutical industry. Alongside, 
further lack of brand new products is 
expected with highly increased 
competitiveness and a furious fight for 
market shares and global customers' 
loyalty.  
 
2. Research objectives  
We aim trying to find out how marketing 
management practices are important and in 
direct relation with a business performance 
of the world pharmaceutical companies. 
Moreover, we would like to evaluate how 
decisive is a marketing management in the 
strategic orientation of pharmaceutical 
companies and in which way it influences 
a strong consolidation process of the world 
pharmaceutical industry.   
 
3. Globalization in the world 
pharmaceutical industry 
We can stipulate that the globalization is 
almost a synonym for a modern economy. 
Nowadays the global competition is 
mostly based on the knowledge and 
technology and ability to serve the 
customers properly, swiftly and repeatedly. 
OECD defines globalisation as ''Spreading 
and deepening of companies performance 
with the target to produce and sell goods or 
services on multiple markets (OECD 1993, 
p.73)''. Later definition of globalization 
from OECD (OECD 1994, p.55) says that 
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''More precisely we may define 
globalisation as a developing pattern of 
international business cooperation, which 
includes investments, trade and 
contractory ways of cooperation, and 
targets the development of products, 
production, procurement and marketing. 
Such kind of international performance 
enables the companies to conquer new 
markets, use their technological and 
organisational advantages and to lower the 
costs and risks.'' Globalization is thus 
strongly related with the increased 
mobility and competition.  The most active 
subjects of the globalization process are 
definitive transnational or multinational 
corporations. We may argue that the 
following characteristics are significant for 
their performance, especially taken into 
consideration as the example the 
multinational pharmaceutical companies: 
 
- multinational pharmaceutical 
companies have had a strong market 
position on the most important and 
strategic world markets with holding of 
considerable market shares, 
- they globally integrate and connect 
their business performance, so national 
identity is no longer important, 
- they perform a flexible purchasing 
management strategy, 
- have had a global network structure of 
production, 
- have had a global network organisation 
of research and development activities, 
- have built a global marketing 
organisation structure which supports a 
dedicated market orientation and a 
strategic priority focus to customers. 
 
We may even emphasize that the 
globalization is in its core meaning a 
complex, market conditioned world 
process, which is related and driven by a 
whole palette of elements of marketing 
way of thinking and performing, sudden, 
fast changes and ever-changing ways of 
doing business, alongside an increasing 
competition and competitiveness, in a 
strive to optimally identify changing needs 
of the world customers and to ability to 
satisfy their longterm needs. We may say 
that it is very important to have in mind to 
know how to detect the needs of customers 
and how to satisfy them on a longterm 
basis. We may emphasize as well that the 
customers should be treated as the most 
precious value of a company. This is a way 
we underline that the globalisation is a 
market driven process. Thus in a process 
of the globalization it is core to be fast, to 
be strongly market oriented, to have loyal 
customers, to be innovative, to have proper 
knowledge, to be able to learn fast, to have 
proper information and to take quick 
decisions. Drucker (1992, p.86) mentioned 
five the most important elements of 
development which would influence 
greatly the strategies, structure and 
performance of future companies: 
- '' Economic relations would be 
performed in the direction among trade 
blocs instead of countries, 
- business performance would be more 
and more matter of strategic alliancing, 
which would be integrated into a world 
economy, 
- restructuring of business would be 
intensifying and more globalising, it 
would be important to have 
information and knowledge, 
- strategic management of companies 
would be decesive for a competitive 
success, 
- intensive market orientation of 
companies would be a core advantage 
for achieving a competitive advantage 
over competitors ''. 
 
We may say that the world pharmaceutical 
industry has been in the intensive 
processes of the concentration and 
consolidation for a period of over 15 years. 
We may argue that research & 
development and marketing activities are 
two the most important and strategic 
priorities of  the pharmaceutical companies 
and into which the greatest part of funds 
are being invested as well. According to 
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our research, we may say that the main 
strategic reasons for the intensive 
consolidation processes of the world 
pharmaceutical industry, are the following: 
 
- lack of brand new products to drive 
sales growth further, 
- fast globalisation processes of the 
world economy, 
- huge investments needed for R&D 
activities, 
- global marketing and sales activities 
which need large investments as well,   
- increased competitiveness, 
- changed structure of the competitors, 
- world reforms of the healthcare 
systems, 
- increased importance of the regulatory 
issues (registrations, intellectual 
property rights, litigations). 
 
According to our research study and 
findings, there have been more than 10,000 
various alliances formed in the world 
pharmaceutical industry in the last decade 
(Datamonitor 2005, p.67). We have found 
out the consolidation processes have been 
carried out practically in all three sectors 
(innventive - original pharmaceutical 
companies, generic producers and 
specialists) of the world pharmaceutical 
industry. The concentration process has 
practically created brand new 
phramaceutical players; however some 
previously well-known pharmaceutical 
firms have practically disappeared from 
the global market scenery. For example, 
the world leading pharmaceutical company 
Pfizer has been created from 6 big 
international players, including  Pfizer 
itself, Warner Lambert, Upjohn, Searle and 
Pharmacia, and Wyeth, respectively. We 
may argue as well that the world 
pharmaceutical industry has become more 
and more oligopolistic indeed. We may 
entirely agree with Knickerbrocker theory 
of oligopolististic reaction 
(Knickerbrocker 1973, p.69) which says, 
that ''Oligopolistic companies, as 
minimizators of taking risks in avoidance 
of destroying effects of competition follow 
each other to new markets to protect their 
own interests. It is significant that the 
action of one player creates a reaction of 
the other competitors, an action creates a 
reaction and so the story of oligopolisation 
is going on.'' We may conclude that 
Knickerbrocker's theory perfectly 
illustrates and explains a consolidation 
process of the world pharmaceutical 
industry. Consolidation processes are 
continuing to speed up as the 
pharmaceutical companies try to follow 
their competitors' strategy of  M&A 
(Mergers and Acquisitions) in endeavour 
to maintain their global market position 
and a long-term competitiveness.  
 
It is thus evident that some stand-alone 
pharmaceutical companies are not able to 
satisfy longterm and ever-changing market 
needs and customers' expectations, to 
invest heavily into R&D and marketing 
activities in endeavour to bring new 
products to global markets and materialize 
them properly. We can argue that this 
process enables pharmaceutical companies 
new development circles and their long-
term development and growth. Formation 
of partnerships for a sake of the 
maintaining long-term competitiveness is 
today one of the most usable strategies in 
the world pharmaceutical industry. We 
may argue that pharmaceutical companies 
make alliances in endeavours to create 
common synergies and to better exploit 
their common assets, knowledge, product 
life cycles and moreover to upgrade 
marketing management strategies. Thus 
we may argue that the most important and 
strategic activities of creating common 
strategies for the pharmaceutical 
companies are:  
 
- research and development (R&D), due 
to creating of brand new products,  
- products, due to drive the sales growth 
and gain market shares, 
- markets, due to create geographic and 
market expansion, 
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- marketing and sales, due to enforce 
marketing and sales activities to 
compete on the global markets and to 
drive further sales growth. 
 
We may say as well that due to a 
complexity in the pharmaceutical industry 
it is not unusual that the pharmaceutical 
companies tend to form partnerships and to 
compete at the same time. They can 
cooperate on some particular projects (for 
example R&D projects), however they 
compete strongly for particular market 
shares. We have found out in our research 
that this is so called ''C and C phenomena'' 
as we may even call it ''Co-opetition'' 
(cooperation and competition at the same 
time) (Zineldin 2004, p.45).  
 
Pharmaceutical companies tend to 
internationalise and globalise their 
business activities sooner as in the past due 
to a market liberalisation, increased 
competitiveness and a need to reach 
considerable economies of scale.    
 
Table 3: Overview of pharmaceutical 
alliances in the 2006 , 2007 and 2008 
 
Target - 
taken-over 
company 
Acquirer Creating of 
synergies 
Schering 
AG, 
Germany 
Bayer, 
Germany 
R&D, 
markets, 
marketing&
sales 
Serono, 
Switzerland 
Merck 
KGaA, 
Germany 
R&D, 
markets, 
marketing&
sales 
Schwarz 
Pharma, 
Germany 
UCB, 
Belgium 
R&D, 
products, 
markets, 
marketing&
sales 
Altana 
Pharma, 
Germany 
Nycomed, 
Denmark 
R&D, 
markets, 
products, 
marketing&
sales 
Kos 
Pharmaceuti
cals, USA  
Abbott, USA R&D, 
products 
Organon 
BioSciences
, the 
Netherlands 
Schering-
Plough, 
USA 
R&D, 
markets, 
products, 
marketing&
sales 
MedImmun
e, USA 
AstraZeneca, 
UK 
R&D, 
markets, 
products 
(vaccines), 
marketing&
sales 
Merck 
Generics, 
Germany 
Mylan, USA markets, 
products, 
sales 
Wyeth, 
USA 
Pfizer, USA R&D, 
markets, 
products, 
marketing&
sales 
Genentech, 
USA 
Roche, 
Switzerland  
R&D, 
markets, 
products, 
marketing&
sales 
Schering-
Plough, 
USA 
Merck&Co.,
USA  
R&D, 
markets, 
products, 
marketing&
sales 
Source:  adapted from the companies 
official published data 
 
According to that Svetlicic (Svetlicic 1996, 
p. 59) stipulates that '' Modern ways of the 
internationalisation with an aid of network 
formation and strategic alliances enable 
internationalisation without a growth of 
the companies. Today companies decide 
for internationalisation and alliances due  
to: 
- be closer to customers, 
- increase effectiveness, 
- gain a better access to technologies and 
knowledge (know-how), 
- protect them from competitors 
(strategic reasons)''. 
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4. The importance of marketing 
management in the world 
pharmaceutical industry  
World guru of management Drucker, who 
especially emphasized a core importance 
of the marketing way of thinking and 
marketing management for a successful, 
longterm highly competitive business 
performance of the companies, has said 
(1993, p.69) about globalization and 
globalization management the following 
properly: ‘’In the future, there will be two 
types of top managers : those who would 
be able to think globally with a strong 
marketing management committment and 
those jobless’’. Marketing-global way of 
thinking, performance and management 
thus enables companies to put customers 
into the centre of all their business 
activities, and integrally focusing all 
business activities to a common and final 
goal – to be successful in satisfying 
customers’ needs and to be better than 
competitors. It is worth to underline as 
well the importance of innovative 
management and the management of 
changes. As Bartlett and Ghosal 
underlined (1989, p.79), ‘’Successful 
companies of today and tomorrow will be 
those ones, who would be able at the same 
time to satisfy local needs, increase global 
effectiveness and strive for a constant 
inovativeness and concomittant global 
learning’’.   
It comes as a no surprise to us that 
successful companies, and they will be 
successful in the future as well with this 
marketing management practices, know 
how to satisfy their focused customers. In 
these companies marketing and marketing 
management represent business 
philosophy of a whole company instead to 
be just a separate function. This perfectly 
underlines Drucker (1973, p.83), when 
saying ''Marketing is so important that it 
cannot be a stand-alone function. If we 
look upon it from a point of the final 
result, that means from a point of the final 
customer, marketing represents a whole 
business, a whole business performance. 
Care for a marketing must go through all 
the company structures. Business success 
is not dependent upon a producer, but 
upon a customer. Thus whole and 
thoroughly  marketing management 
concept should be the most important one 
in a company, and must prevail over 
innovativeness, organisation structuring, 
financial resources, physical sources, 
productivity, social responsibility and 
demand for a profit making''. Marketing 
way of thinking and marketing 
management are especially important in 
the pharmaceutical industry as 
pharmaceutical companies tend to be 
market oriented and proactive  by 
emphasizing the advantage of their 
pharmaceutical products. They try to 
communicate within regulatory allowed 
frameworks, they strive to build strong 
brand names (trade marks) and to create 
long-term loyalty to final customers. We 
may even say that in a certain way concept 
of the marketing management clearly 
designates a company's business 
philosophy, respectively. We may entirely 
agree with Corstjens' estimation (Corstjens 
1991, p.55) that ''Sector of the 
pharmaceutical industry, despite being 
very specific in the all aspects, is an ideal 
case, how a practice and usage of the 
marketing management concept directly 
relates to a very successful business 
performance of this industrial sector''.  
                                  
According to our research work, we may 
argue that a marketing management is by 
no doubt, besides R&D function, the most 
important function of the innovative 
company's business performance. Thus it 
is important to react and act quickly and to 
be proactive. An urgence of the fast 
adaptation is not just the strategy for 
smaller companies and countries but it is a 
valid strategy of victorious success for the 
bigger firms, too, as changes in the world 
economy and globalization are really fast 
and tremendous. This is why we may 
argue that a marketing way of thinking and 
a marketing management are the decesive 
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factors of strategic business success for the 
pharmaceutical companies in the highly 
globalised and ever-changing world 
market place. We may argue the 
pharmaceutical companies which want to 
be globally the leading ones and sucessful 
business performers in the future, need to 
primarily think entirely and differently 
about customers, markets, 
competitiveness, competitors,  and strategy 
with relation to a structure to reach the 
planned goals. Especially, they need to 
bear in minds that the needs of tomorrow 
customers are different from the needs of 
today’s customers and they do change fast 
and tremendously in a relation to elements 
and facts which are the most important to 
the pharmaceutical industry itself. In that 
relation, we foresee a role of the marketing 
way of thinking and marketing 
management as a decesive, crucial and the 
most important strategic function of a 
particular pharmaceutical company.  
 
5. Findings and conclusions 
The purpose of this paper is to analyse 
whether a marketing management plays an 
important role in the operational and 
strategic performance in the world 
pharmaceutical industry. Using a variant of 
public available data and information, 
predominantly on the business 
performance of world pharmaceutical 
industry, world pharmaceutical markets 
and the development trends within the 
pharmaceutical industry in our research 
work, we have found out that world 
pharmaceutical industry has been changing 
profoundly in the last couple of years. We 
provide empirical evidence that the 
intensive processes of concentration and 
consolidation  have been continuing in all 
three sectors of the world pharmaceutical 
industry. In order to explain this 
phenomenon properly we have analysed in 
details the trends in the world 
pharmaceutical industry  and key reasons 
for such movements. We have found out 
that intensive globalization process 
definitively influences and reinforces a 
consolidation of the world pharmaceutical 
industry. Further on, we may argue that 
increased competitiveness and amended 
structure of competitors which is 
conditioned by a merger and acquistion 
process, impact a strategic orientation of 
the particular world pharmaceutical 
companies. We have found out in our 
research survey that mergers and 
acquisitions prevail more and more as a 
viable strategic orientation for the world 
pharmaceutical companies. However, 
taken into account the analysed data, 
business performance of scrutinized 
pharmaceutical companies and outcomes 
of our research study, we may support the 
hypothesis that marketing management 
plays a predominant and strategic role in 
the world pharmaceutical industry. Further 
on, we may argue that a fast consolidation 
of the world pharmaceutical industry is 
clearly market driven and conditioned 
upon by a typical strategic marketing 
management issues, like: a lack of the 
brand new products, an intensive 
competitiveness, a fast globalisation, an 
increased global marketing and sales 
activities, a changed structure of the 
competitors, a fierce fight for the global 
market shares and customers' loyalty. We 
may argue that a marketing management is 
going to play even more important and 
especially strategic role in the future 
globalisation and concentration processes 
of world pharmaceutical industry which 
we may foresee they will intensively 
continue.  We may further conclude that a 
future strategic development of the world 
pharmaceutical industry will be 
predominantly dependent on the strategic 
marketing management issues that the 
pharmaceutical companies will be capable 
to understand, develop and imply properly 
in their operational and strategic business 
performances.            
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